#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arrhythmogenic right ventricular dysplasia Optic glioma Fatty acid oxidation disorder Adrenoleukodystrophy Systemic lupus erythematosus Sexually transmitted disease Small cell lung cancer limited stage Hepatitis B Endometrial adenocarcinoma Oesophageal carcinoma Anti-glomerular basement membrane disease Congenital growth hormone deficiency Brain stem glioma Inborn error of metabolism Hereditary ataxia More trials…

    Learn about Rare Diseases

    Idiopathic pulmonary fibrosis – Treatment Marginal zone lymphoma refractory Amyotrophic lateral sclerosis Leiomyosarcoma metastatic – Trials in Disease Urea cycle disorder Cystic fibrosis lung – Life with Disease Pelizaeus-Merzbacher disease – Treatment Mast cell activation syndrome – Treatment Haemolytic uraemic syndrome – Treatment Adrenogenital syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Flortaucipir (18F) Nazartinib Dordaviprone Methohexital Sodium Rintatolimod Tryptophan AMODIAQUINE Dexamethasone Isonicotinate Belimumab Dabrafenib Timrepigene Emparvovec Ibuprofen Arginine Sulfamethoxazole 177Lu-Rhpsma-10.1 TORASEMIDE Gskvx000000014593 LIGUFALIMAB Tisotumab Vedotin Carbasalate Calcium L-Acetylleucine More therapies…

    Learn about Your Condition

    Joint stabilisation Thymoma malignant Mast cell activation syndrome Thyroid cancer metastatic Genital herpes simplex Immunodeficiency Pemphigoid Immune thrombocytopenia Tonsillitis Vestibular disorder Immunodeficiency congenital Amyloidosis Vitamin D deficiency Aplastic anaemia Breast cancer male More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Fabry’s disease

  • Title: Evaluating low-dose prednisone with standard therapy to improve heart function in patients with cardiac manifestations of Fabry disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Prednisone
    Poland

  • Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease

    Recruiting

    4 1 1
    Investigated Drugs:
    • Pegunigalsidase Alfa
    Austria France Norway Spain

  • A Study of Migalastat Safety and Effects in Children Aged 2 to 12 Years with Fabry Disease and Suitable Gene Changes

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Fabry’s disease
    Belgium Germany Spain

  • Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Fabry’s disease
    Investigated Drugs:
    • AGALSIDASE BETA
    • Migalastat
    • Venglustat
    Austria Czechia Denmark France Germany Greece +5

  • Long-Term Safety Study of ST-920 Gene Therapy for Patients with Fabry Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Fabry’s disease
    Investigated Drugs:
    • Isaralgagene Civaparvovec
    Germany

  • Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Fabry’s disease
    Investigated Drugs:
    • Pegunigalsidase Alfa
    Belgium Czechia Denmark Italy Norway
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!